Nama Insights

Madrigal Pharmaceuticals (MDGL)

Healthcare · Biotechnology · NASDAQ

Madrigal Pharmaceuticals (MDGL) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $9.22B and a free-cash-flow yield of -2.2%. Over the most recent reported fiscal year, revenue grew 432.1%. Nama's AI scorecard rates it Sell, 3.8 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Sell · 3.8/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Trailing · -15.5% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-38.4%
How far the last close sits under the highest price of the past five years.
Market cap$9.22B
Trailing P/E—
Price / book14.7
Price / sales6.5
FCF yield-2.2%
Dividend yield—
Gross margin91.0%
Operating margin-10.7%
Net margin-10.9%
Revenue growth (YoY)+432.1%
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta-1.0
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

MDGL earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate $1.92). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 3, 2026 $1.83 -$0.87 +310.3% $431.27M
Q2 2026 Jul 30, 2026 -$1.99 -$2.23 +10.8% $364.25M
Q1 2026 May 6, 2026 -$1.38 -$4.14 +66.7% $311.34M
Q4 2025 Feb 19, 2026 -$2.57 -$0.88 -192.1% $321.08M

MDGL analyst price target

Median target $660.00 from 18 analysts, ranging $479.00 – $962.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live MDGL data on Nama Insights →

MDGL FAQ

Is MDGL a buy?
Nama's AI scorecard currently rates Madrigal Pharmaceuticals Sell (3.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MDGL report earnings?
Madrigal Pharmaceuticals's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $1.92.
What is the MDGL price target?
The median analyst price target from 18 analysts is $660.00, with a range of $479.00 – $962.00.
Is MDGL Shariah compliant?
Nama's AAOIFI-style screen reads Madrigal Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.